Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GSK
Strong BuyAPPROVEGSK plc · Healthcare · United Kingdom · $101.8B · Avg Vol: $195M/d
GSK generates strong cash flow from vaccines, HIV and specialty medicines, funds a covered dividend, and has resolved the bulk of its largest litigation overhang through settlements, with a good quality score (Q75) and a cheap value score. The 2.0% consensus trim is modest. Nothing adverse is known on accounting or solvency.
COMPANY DESCRIPTION
GSK plc is a global biopharmaceutical giant focused on the research, development, and commercialization of innovative vaccines and specialty medicines. The company holds a dominant market position in the global vaccine industry and is a leader in HIV therapeutics through its majority-owned ViiV Healthcare joint venture. Following the spin-off of its consumer healthcare division, GSK operates as a pure-play, research-driven healthcare leader with robust R&D pipelines in infectious diseases and immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39.7B | 41.0B | 42.5B | 44.2B | 3.7% | 45.2B | 45.9B | 48.1B | 4.3% |
| EPS | 20.54 | 6.66 | 3.48 | 7.65 | -28.1% | 3.22 | 7.71 | 8.34 | 4.4% |
| Shares | 2.0B | 2.0B | 2.0B | 2.0B | 0.0% | 2.0B | — | — | — |
| Debt | 28.4B | 24.4B | 23.0B | 24.0B | -5.5% | 24.9B | — | — | — |
| Equity | 14.3B | 18.1B | 18.5B | 22.2B | 15.6% | — | — | — | — |
| Op CF | 10.0B | 9.2B | 8.9B | 10.5B | 1.5% | 11.3B | — | — | — |
| Inv CF | -11.9B | -2.2B | -1.7B | -5.7B | — | — | — | — | — |
| Fin CF | 1.1B | -7.6B | -6.4B | -5.0B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GSK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GSK | GSK plc(you) | $101.8B | 86 | Strong Buy |
| SAN.PA | Sanofi | $107.2B | 94 | Strong Buy |
| PFE.DE | Pfizer Inc. | $158.9B | 88 | Strong Buy |
| GILD.MX | Gilead Sciences, Inc. | $181.0B | 85 | Strong Buy |
| NVO | Novo Nordisk A/S | $201.6B | 88 | Strong Buy |
| BAYN.DE | Bayer Aktiengesellschaft | $55.6B | 81 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $136.0B | 99 | Strong Buy |
| AMGN | Amgen Inc. | $233.8B | 89 | Strong Buy |
| NOVN.SW | Novartis AG | $290.6B | 86 | Strong Buy |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $72.3B | 67 | Buy |
Peer medians: ROE 1.9% · P/E 24.0x · Gross margin 52.2%